Table 2 Comparison of baseline characteristics between the non-severe PJP and severe PJP groups
|  | Total (n = 178) | Non-severe PJP (n = 61) | Severe PJP (n = 117) | P value |
|---|---|---|---|---|
Age, years | 60.0 ± 11.8 | 57.7 ± 11.7 | 61.2 ± 11.7 | 0.066 |
Male sex | 96 (53.9) | 33 (54.1) | 63 (53.8) |  > 0.999 |
Ever smoker | 66 (37.1) | 22 (36.1) | 44 (37.6) | 0.871 |
Underlying disease | Â | Â | Â | Â |
 Hematological malignancy | 58 (32.6) | 23 (37.7) | 35 (29.9) | 0.315 |
 Solid cancer | 70 (39.3) | 18 (29.5) | 52 (44.4) | 0.075 |
 Organ transplantation* | 42 (23.6) | 17 (27.9) | 25 (21.4) | 0.356 |
 Autoimmune disease | 31 (17.4) | 8 (13.1) | 23 (19.7) | 0.306 |
Diabetes mellitus | 45 (25.3) | 16 (26.2) | 29 (24.8) | 0.857 |
Chronic kidney disease | 30 (16.9) | 8 (13.1) | 22 (18.8) | 0.403 |
Previous steroid use** | 27 (15.2) | 6 (9.8) | 21 (17.9) | 0.189 |
Prophylaxis with TMP/SMX | 9 (5.1) | 3 (4.9) | 6 (5.1) |  > 0.999 |
Initial laboratory tests | Â | Â | Â | Â |
 Albumin, g/dL (n = 177) | 2.4 ± 0.5 | 2.6 ± 0.6 | 2.3 ± 0.4 |  < 0.001 |
 C-reactive protein, mg/dL (n = 177) | 12.3 ± 8.9 | 7.6 ± 6.6 | 14.7 ± 9.0 |  < 0.001 |
 Lactate dehydrogenase, IU/L (n = 153), median [IQR] | 375.0 [271.0–474.5] | 325.0 [245.8–407.3] | 407.0 [296.0–532.0] | 0.005 |
 Procalcitonin, ng/mL (n = 126), median [IQR] | 0.13 [0.06–0.41] | 0.09 [0.00–0.50] | 0.13 [0.06–0.44] | 0.149 |
 β-D-glucan, pg/mL (n = 132), median [IQR] | 72.8 [0.0–301.6] | 38.9 [0.0–269.2] | 94.2 [0.0–308.4] | 0.384 |
 Absolute neutrophil counts, cells/μL, median [IQR] | 2775.0 [1547.5–5172.5] | 2480.0 [1570.0–3920.0] | 3110.0 [1490.0–6085.0] | 0.167 |
Neutropenia within 6Â months before admission | 81 (45.5) | 30 (49.2) | 51 (43.6) | 0.527 |